Poor outcome of oesophageal adenocarcinoma after prior antireflux surgery  by Mitchell, E.M. et al.
lable at ScienceDirect
International Journal of Surgery 7 (2009) 566–569Contents lists avaiInternational Journal of Surgery
journal homepage: www.thei js .comPoor outcome of oesophageal adenocarcinoma after prior antireﬂux surgery
E.M. Mitchell, N. Pal, J.P. Kalyan, M. Rhodes, M.P.N. Lewis*
Department of Upper Gastrointestinal Surgery, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UKa r t i c l e i n f o
Article history:
Received 3 August 2009
Received in revised form
8 September 2009
Accepted 24 September 2009
Available online 13 October 2009
Keywords:
Adenocarcinoma
Oesophagus
Oesophagectomy
Gastro-oesophageal reﬂux
Fundoplication* Corresponding author at: Department of Sur
University Hospital, Colney Lane, NorwichNR47UY, UK
E-mail address: michael.lewis@nnuh.nhs.uk (M.P.N
1743-9191/$ – see front matter  2009 Surgical Asso
doi:10.1016/j.ijsu.2009.09.009a b s t r a c t
Aims: Gastro-oesophageal reﬂux disease is an important risk factor for oesophageal adenocarcinoma, but
abolishing reﬂux through surgery has not been shown to reduce this risk. The purpose of this study is to
report on adenocarcinomas occurring after previous antireﬂux surgery and their long-term outcome.
Patients and methods: Six hundred and forty three patients underwent surgical resection in our unit for
oesophagogastric adenocarcinoma between 2000 and 2009. Nine of these had antireﬂux surgery
a median of 6.9 (mean of 9.3) years previously. Clinical and pathological characteristics and outcome (in
terms of survival) are described for this patient group. The patients who had prior antireﬂux surgery
were compared to matched control patients for disease free survival.
Results: Disease free survival in our antireﬂux patients was 25.1% as compared to 72.1% in controls at
3 years. (Log rank test p ¼ 0.004).
Conclusions: Patients who have undergone antireﬂux surgery for chronic gastro-oesophageal reﬂux
disease can develop adenocarcinoma and need to be monitored closely. The outcome following surgery
appears greatly worse for patients with previous antireﬂux surgery than age/sex/stage/treatment
matched controls in this small study.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The popularity of antireﬂux surgery for the management of
gastro-oesophageal reﬂux disease (GORD) has increased with the
introduction of laparoscopic techniques though it has not been
shown to reduce the risk of adenocarcinoma of the oesophagus in
patients with GORD.1 Accordingly a small proportion of patients
presenting with adenocarcinoma of the oesophagus and oesophago-
gastric junction have had prior antireﬂux surgery. In this study we
present a series of nine such patients who developed oesophageal
adenocarcinoma up to 28 years after previous surgery for gastro-
oesophageal reﬂux disease.
Cancer of the right colon appears to have a worse recurrence
rate following surgery in those patients who have had a prior
appendicectomy.2 It has been postulated that the presence of
altered tissue planes from previous surgery may affect the behav-
iour of such tumours. In order to examine if previous oesophago-
gastric surgery affect tumour behaviour and therefore clinical
outcome, we compared the group to case-matched controls, look-
ing speciﬁcally at differences in disease free survival, and operative
variables such as blood loss and operating time; the hypothesisgery, Norfolk and Norwich
. Tel./fax:þ44 01603 287 583.
. Lewis).
ciates Ltd. Published by Elsevier Ltbeing that the altered tissue planes following antireﬂux surgery
may adversely affect subsequent tumour behaviour.2. Patients and methods
2.1. Patient selection
Patients with adenocarcinoma of the lower oesophagus and
oesophagogastric junction who underwent surgical resection for
this tumour and had previous antireﬂux surgery were identiﬁed
from a local prospective database of oesophagogastric cancers
covering the period from 1 January 2000 to 1 February 2009. Their
medical recordswere reviewed anddata on demographics, type and
date of antireﬂux surgery, tumour stage (TNM), treatment (resec-
tion, chemotherapy or palliative care), outcome (disease free
survival), blood loss andoperating timewere recorded.Details of the
initial antireﬂux surgery and long-term success (clinical control of
symptoms, pH/manometry studies) were included where available.
Four controls per surgically resected index case were also
identiﬁed from the database, matched by age (within 10 years), sex,
tumour pathological TNM stage (identical histological TNM stage),
site of tumour and treatment (surgery with or without neoadjuvant
therapy). Their records were analyzed for survival, and operative
details as for the cases. All cancer resections were performed at
the Norfolk and Norwich University Hospital, Norwich, UK. Alld. All rights reserved.
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oesophagogastric junction treated by oesophagogastrectomy.
2.2. Statistical analysis
The survival times calculated compare study patients with age/
sex/tumour TNM stage/treatment matched controls. Actuarial
survival was calculated using Kaplan–Meier analysis. Disease free
survival rather than overall survival was used in this study in order
not to bias survival data by non-cancer deaths. The log rank testwas
used to assess differences in survival between the study group and
matched controls. SPSS was used for these calculations.
Descriptive statistics were calculated using Microsoft Excel.
Kaplan–Meier statistics were performed using SPSS. Other
comparisons between the study group and the control group were
done using Mann–Whitney U-test.
3. Results
3.1. Patient demographics and surgical details
Nine patients were identiﬁed who had undergone previous
antireﬂux surgery among the 643 patients presenting with oeso-
phageal malignancy and undergoing resection between 2000 and
2009 at theNorfolk andNorwich UniversityHospital. The clinical and
pathologic ﬁndings for these patients are summarized in Table 1.
These seven men and two women had a mean age of 67.1 years
(range 56–78 years) at the time of oesophageal cancer diagnosis.
Four of these patients had undergone previous open antireﬂux
procedures between 1978 and 1989. The remaining ﬁve patients
underwent laparoscopic procedures between 1998 and 2006.
Patient 8 had undergone a second redo fundoplication procedure in
2006 following a prior laparoscopic Nissen’s fundoplication, after
functional studies conﬁrmed recurrent severe reﬂux.
Patients 2, 3, 4 and 9 were asymptomatic after the initial
antireﬂux procedure. Patients 4 and 9 had a 24 h pH study and
oesophageal manometry that conﬁrmed success of the antireﬂux
procedure. Patients 1 and 7 had initial symptomatic control afterTable 1
Clinical and pathologic ﬁndings in nine patients who developed adenocarcinoma after a
Patient Age
(years)
Sex Antireﬂux procedure Symptom control
Type Year Achieved? Evidence
1 75 Male Open Belsey 1985 Initially Clinical
2 77 Male Open
fundoplication
1989 Yes Clinical
3 78 Male Open
fundoplication
1987 Yes Clinical
4 56 Male Lap Nissen’s 1998 Yes Clinical &
physiological
5 68 Male Open Nissen’s 1978 No Clinical
6 61 Male Lap Nissen’s 2003 No Clinical &
physiological
7 69 Female Repair hiatus
hernia
(Lap Chole)
1999 Initially Clinical
8 63 Female Lap Nissen’s,
redo
2005,
2006
No Clinical &
physiological
9 57 Male Lap Nissen’s 2006 Yes Clinical &
physiological
Times are all displayed to one decimal place.
bPatient received palliative chemotherapy, not adjuvant.
a Presence of Barrett’s in resected specimen not commented on by pathologist.
c Exact surgery date unavailable. Interval calculated using 1st January as antireﬂux pr
d Antireﬂux surgery – cancer interval calculated using date of ﬁrst antireﬂux proceduthe antireﬂux procedure; however symptoms had recurred at the
time of oesophageal cancer diagnosis. Patients 5 and 6 experienced
GORD symptoms soon after antireﬂux surgery had been performed.
In patient 6 a 24 h pH study conﬁrmed recurrent severe acid reﬂux.
Patient 8 initially had an unsuccessful antireﬂux procedure,
conﬁrmed by a 24 h pH study. The second procedure in 2006
successfully controlled reﬂux symptoms.
The interval between initial antireﬂux surgery and cancer
diagnosis varied from 1.7 to 28.4 years (median time 6.9 years,
mean 9.3 years).
The nine patients underwent two stage Ivor Lewis procedures
with or without neoadjuvant chemotherapy depending on the
presenting stage. Operative histology showed that four patients
had T1N0, one had T1N1, three patients had T2N0 and one patient
had T3N1 disease.
3.2. Survival
For the study patients the median follow up period was 2.9 years
(mean3.8 years, range0.5–6.8 years), and for thecasecontrolsmedian
follow up was 4.8 years (mean 4.9 years, range 1.0–9.1 years). Table 2
shows median age of patients in study and control groups, as well as
the median operating time and blood loss at surgery.
Disease free survival was calculated for both groups using
a Kaplan–Meier survival curve, shown in Fig. 1. Three year disease
free survival was 25% (95% conﬁdence interval (CI) 0–55%) for study
patients, and 72% (95% CI 56–88%) for controls (p ¼ 0.004). This
shows that there is a statistically signiﬁcant difference in disease
free survival seen, and that patients who had previous antireﬂux
surgery in this study did worse after their cancer diagnosis than
those who had not had previous surgery.
4. Discussion
This studydescribesninepatientswhodevelopedadenocarcinoma
of the loweroesophagusoroesophagogastric junction some timeafter
antireﬂux surgery. These ﬁndings obviously challenge the view that
antireﬂux surgery prevents the development of adenocarcinoma inntireﬂux surgery.
Neoadjuvant
chemotherapy?
Histology Surgery to
cancer (years)
Survival after
cancer diagnosis
T
stage
N
stage
Barrett’s
present?
Time
(years)
Outcome
No T2 N0 Yes 16.1 1.0 Died
Yes T1 N1 a 3.5 1.2 Died
Yes T2 N0 a 14.9 0.6 Died
Yes T1 N0 a 6.9 3.9 Alive
No T1 N0 Yes 28.4c 1.8 Died
No T1 N0 Yes 2.2 2.1 Dead
No T1 N0 Yes 7.7 2.5 Alive
No T3 N1 No 1.7d 1.8 Died
Yes T2 N0 a 2.5 0.5 Alive
ocedure date.
re.
Table 2
Differences between the study group and control group for age, blood loss and
operating time.
Study
groupa
Control
groupb
p value (Mann–
Whitney U-test)
Age (years) Median 68 69 p ¼ 0.922
Mean 67.1 66.9
Standard
deviation
(8.4) (9.5)
Blood Loss (ml) Median 1348 500 p ¼ 0.051
Mean 1194 585
Standard
deviation
(588) (393)
Operating time
(min)
Median 210 215 p ¼ 0.869
Mean 218 206
Standard
deviation
(67) (47)
a Study group – patients operated on for oesophageal adenocarcinoma who had
previous antireﬂux surgery.
b Controlgroup–age/sex/tumourstage/treatmentmatchedcontrolpatentsoperated
on for oesophageal adenocarcinoma who have not had previous antireﬂux surgery.
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However, as ﬁve of these patients had symptoms suggestive of
recurrent reﬂux by the time of their cancer diagnosis (and therefore
possibly ineffective antireﬂux surgery), the cancer risk prevention of
effective antireﬂux surgery cannot be commented on.
Median follow up post oesophagogastrectomy for our patients
has been fairly short at 2.9 years. We are aware this is a small study,
however, initial analysis suggests that long-term survival in
patients who develop adenocarcinoma after antireﬂux surgery is
worse than case-matched controls. The presence of altered tissue
planes and scar tissue around the oesophagogastric junction that
follows antireﬂux surgery may alter the kinetics of invasion of
adenocarcinoma. This may explain the worse outcome when
comparing these patients with controls. This phenomenon
has been seen in adenocarcinoma of the caecum with prior
appendicectomy.2 Certainly we have found anecdotally that hiatal
dissection is more difﬁcult in these patients (even if this is not
reﬂected in a statistically longer operating time) although it should
be added that circumferential resection margins were clear of
tumour in all nine resections. Accurate endoscopic ultrasound isFig. 1. Kaplan–Meier survival curve showing disease free survival for operated patients
with oesophageal adenocarcinoma. Study patients have had prior antireﬂux surgery.
Control patients are age/sex/tumour stage/treatment matched controls. 95% Conﬁ-
dence intervals are shown, with the lighter lines. Three year disease free survival is
signiﬁcantly lower in the study group (p ¼ 0.004, log rank test).particularly difﬁcult where the tumour is located at the gastro-
oesophageal junction in such patients. Other possible reasons for
this difference in survival may include greater blood loss, and
morbidity related to blood loss, however, the differences between
the study groups are not signiﬁcant in this analysis. Previous anti-
reﬂux surgery may disrupt small lymphatic channels during lower
oesophageal mobilisation. This may disrupt the normal patholog-
ical locoregional behaviour of tumours arising at this site in the
future. Such tumours may be more prone to haematological spread
rather than lymphatic; indeed it is interesting that of these nine
cases, seven had negative regional nodes. There may also poten-
tially be subtle differences in tumour biology without continued
acid reﬂux following antireﬂux surgery. A ﬁnal possibility is that
prior antireﬂux surgery may hide potentially metastatic cardiac
nodes from the histopathologist dissecting the operative specimen.
This may result in a false negative nodal status.
There are a number of limitations to this study. It is a retro-
spective case series where the numbers of patients are small, thus
our results must be interpreted with caution. Missing data (usually
regarding the original antireﬂux procedure and GORD symptom
control) were obtained from the GP or patient, and may be affected
by recall bias. All oesophageal resections were performed at the
Norfolk and Norwich University Hospital, representing a one
institution perspective only. The initial antireﬂux procedures varied
(open vs. laparoscopic technique), and were performed at different
centres. Objective assessment of the effectiveness of the antireﬂux
procedure (functional studies), was available for four patients only
who had laparoscopic Nissen’s fundoplication. Informationwas not
available on the presence of Barrett’s metaplasia at the time of
antireﬂux surgery for a proportion of our patients.
Our paper adds to the growing number of case reports3 and
publications on adenocarcinoma after antireﬂux surgery. A large
retrospective cohort study spanning 32 years conducted byYe et al.4
identiﬁed oesophageal adenocarcinomas arising in 16male patients
after antireﬂux surgery. The presence of Barrett’s oesophagus was
not commented on in this study. Another recent Swedish study5
reported on seven patients (male) who developed adenocarcinoma
a minimum of 5 years after antireﬂux surgery. Barrett’s oesophagus
was identiﬁed adjacent to the tumour in all seven cases.
Csendes et al.6,7 have reported on six patients (ﬁve men and one
woman) who developed adenocarcinoma 4–18 years after under-
going antireﬂux surgery for Barrett’s oesophagus in a prospective
study. These patients were all suffering from GORD symptoms and
pH studies demonstrated severe acid reﬂux in two of the patients.
Similarly, O’Riordan et al.8 reported on two patients who developed
adenocarcinoma at 4 and 7 years after antireﬂux surgery for
Barrett’s oesophagus. Both patients had signiﬁcantly abnormal pH
studies after antireﬂux surgery, suggesting that there had been
ineffective control of reﬂux. Spechler et al.9 reported on a male
patient with Barrett’s oesophagus who developed adenocarcinoma
7 years after antireﬂux surgery. Collectively, these studies suggest
that many patients who develop adenocarcinoma after antireﬂux
surgery typically have GORD symptoms at the time of diagnosis.
This implies that the antireﬂux procedure was ineffective in
controlling reﬂux though it is likely that early tumours may either
cause some degree of dysphagia or dyspepsia that may mimic
symptoms of chronic reﬂux. In some patients, functional studies
have conﬁrmed acid reﬂux in these patients.
Our study shows a mixed pattern. Five patients had symptom-
atic reﬂux (two conﬁrmed by functional studies), and four patients
were asymptomatic, two of which had functional studies proving
that the antireﬂux procedure was successful. There was a wide
variation in the time period from antireﬂux procedure to devel-
opment of tumour (up to 28.4 years) and the symptom pattern may
reﬂect a long-term lessening of the effect of the antireﬂux surgery.
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Patients who have undergone antireﬂux surgery for chronic
GORDcandevelopadenocarcinoma,oftenmanyyearsafter the initial
antireﬂux surgery. The outcome of these tumours appears worse
than case-matched controls in this study. This may be explained by
the altered tissue planes and subsequent altered tumour growth and
disrupted lymphatics, ormay involve other (as yet unknown) factors.
Our ﬁndings here need to be conﬁrmed by larger studies.
Long-term studies, with objective evaluations of antireﬂux
surgical success are needed to understand the possible preventative
role of antireﬂux surgery in the aetiology of oesophageal adeno-
carcinoma. In patients with established Barrett’s oesophagus estab-
lished screening should continue even after antireﬂux surgery, and
recurrence of GORD symptoms should be investigated thoroughly.
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